Revenue

MetaComp and Stable are building a compliant, high-speed payment network with stablecoins, aiming to disrupt the trillion-dollar cross-border market.

Affluent buyers in Southeast Asia are trading property for lifestyle, fueling a 230% boom in branded residences. Why is experience the new ultimate luxury?

A new healthcare city linked to China's largest western HSR hub promises to revolutionize medical access for millions, blending urban planning with wellness.

A breakthrough clinical trial and a savvy financial move could net Fractyl Health $18M to advance its novel obesity treatment beyond the GLP-1 boom.

A decade-long wait ends as the FDA approves a new 1st-line therapy for HER2+ breast cancer. See how ENHERTU reshapes patient outcomes and market dynamics.

A familiar quit-smoking app has been rebuilt into a powerful research tool, powering Australia's largest cessation trial and setting a new standard.

Biotech Immunome plans a massive stock offering. A deep dive into the high-stakes bet on its cancer pipeline and what it means for investors.

Boise Cascade's acquisition of Holden Humphrey aims to reshape the Northeast building materials market, consolidating its power and expanding its product lines.

A $1.2M investment isn't just charity; it's a strategic push for 'whole-person health' aimed at fixing the Pacific Northwest's deepest care gaps.

Ford hits the brakes on its aggressive EV plan, pivoting to profitable hybrids and a bold new venture in battery energy storage. What does this mean?

IO Biotech’s cancer vaccine posts impressive 5-year survival data, but a narrow miss in its pivotal trial creates an uncertain path in a competitive market.

Beyond a routine board re-election, Heidmar Maritime is doubling down on an AI-driven strategy to navigate the volatile tanker market. Here's what it means.

Kodiak Sciences is raising crucial capital with a stock offering, diluting investors but fueling its late-stage retinal drugs. Is this a necessary lifeline or a red flag?

A modest dividend payout belies a massive ambition. Canterbury Park is betting its future not on the track, but on building an entire community around it.

Verastem Oncology taps industry heavyweights for its leadership, signaling a bold new strategy to accelerate its cancer pipeline and grow its market share.

Tiziana's CEO doubles down with a major share purchase, signaling deep faith in a novel MS drug, even as market signals send mixed messages.

Beijing touts its Sanjiangyuan project as a win for ecology and herders. But beyond the state narrative lies a complex story of coercion and cultural risk.

A new report forecasts modest 2.6% growth for US construction in 2026, driven by data centers, water, and aviation, but challenged by major hurdles.

In a volatile market, Edupoint's award-winning SIS proves that steady integration and fiscal discipline can deliver more resilient returns than fleeting trends.

Mitchell Silberberg & Knupp's new partners reveal a deeper trend: how elite firms are cultivating specialized talent to win in a changing legal market.